Browse Technologies

Displaying 1 - 10 of 30


Systems and Methods for Optical Stimulation of Neural Tissues (Portfolio)

Vanderbilt researchers have developed a novel technique for contactless simulation of the central nervous system.  This involves the use of infrared neural stimulation (INS) to evoke the observable action potentials from neurons of the central nervous system.  While infrared neural stimulation of the peripheral nervous system was accomplished almost a decade ago, this is the first technique for infrared stimulation of the central nervous system. This technology has been protected by a portfolio of issued patents.


Licensing Contact

Ashok Choudhury

615.322.2503

New Clostridium Difficile Recombinant Toxin for Safe Vaccine Development

A structural biology approach has identified a conserved region common to multiple Clostridium toxins. Specific mutations of the protein sequence in this region prevent the toxins from entering into intestinal cells, thereby preventing widespread tissue damage. These recombinant Clostridium toxins may be used to create a multivalent vaccine to protect against multiple species of Clostridium. Furthermore, the recombinant toxin may be used as a safer alternative to the native toxins in vaccine manufacturing. This discovery stems from a collaboration between the laboratories of Dr. Borden Lacy of Vanderbilt University and Dr. Roman Melnyk of the Hospital for Sick Children.


Licensing Contact

Jody Hankins

615.322.5907

Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Jody Hankins

615.322.5907

Small Molecule Theraputics That Target the Muscarinic Acetylcholine Receptor 1 For The Treatment of Alzheimer's Disease

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Neuroscience/Neurology

Systems-Biology Infrastructure to Identify Drug Repurposing Opportunities as Antiviral & Anticancer Therapeutics

Vanderbilt researchers have developed an in-silico screening method to reveal new indications for existing drugs with known protein targets using a novel infrastructure. The infrastructure integrates multiple factors across system-biology models to create a drug discovery pipeline.


Licensing Contact

Janis Elsner

615.343.2430

New antibiotics against new targets in multi-drug resistant microorganisms

New everninomicin antibiotics including a potent bifunctional antibiotic natural product targeting two different and distant ribosomal sites are under development and can be readily produced using synthetic biology. Developing resistance to this bidentate antibiotic should be very difficult for pathogenic microorganisms.


Licensing Contact

Jody Hankins

615.322.5907
Therapeutics
Infectious Disease

New Molecules Clear Chronic Infections by Disrupting Bacterial Energy Production Pathways

New compounds developed at Vanderbilt demonstrate a unique mechanism of broad spectrum activity to stymy antibacterial resistance. The compounds are particularly useful in chronic infections where long term antibiotic therapy fails, because it specifically kills "small colony variants" -- the bacteria that have developed resistance mechanisms. These compounds show promise in treating Methicillin-resistant S. aureus (MRSA), Bacillus anthracis (anthrax), and in overcoming difficult-to-treat infections in bone in cystic fibrosis patients. These compounds could be combined with new (and old) antimicrobial drugs to outwit resistant bacterial infections.


Licensing Contact

Karen Rufus

615.322.4295
Therapeutics

Targeting microRNAs as a Treatment for Vascular Disease

Vanderbilt researchers have identified a highly expressed microRNA crucial in angiotensin induced hypertension; and developed a therapeutic strategy that focuses on local or systemic administration of antisense microRNA to inhibit microRNA expression as treatment for vascular diseases. Promising data in animal models reveals that the inhibition of such microRNA not only prevents fibrosis but also reverses previously established aortic stiffening.


Licensing Contact

Jody Hankins

615.322.5907

Small Molecule Mediated Transcriptional Induction of E-Cadherin and Inhibition of Epithelial-to-mesenchymal Transition


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Oncology

Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Cardiovascular